Melanoma — A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Citation(s)
Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma.